To the Editor Barrett and colleagues1 demonstrated the weight loss effectiveness, comorbidity avoidance, and insurer cost savings of bariatric surgery over glucagon-like peptide-1 (GLP-1) agonist treatment. Let me provide a patient’s personal and out-of-pocket cost (OOPC) perspective. As I aged, I gained weight and found that losing it was difficult. I obtained a GLP-1 prescription and lost about 5% of my body weight at the maximum dose over 2 years.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with William B.
Contact William B., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack